Clinical Trial Update: Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of PNT2258 in relapsed or refractory non-Hodgkin's lymphoma completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• PNT2258

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Lymphoma, Non-Hodgkin's | Phase 2 | Status: COMPLETED | Results posted: 2020-03-10